Recurrent somatic mutations as predictors of immunotherapy response

Immune checkpoint blockade (ICB) has transformed the treatment of metastatic cancer but is hindered by variable response rates. A key unmet need is the identification of biomarkers that predict treatment response. To address this, we analyzed six whole exome sequencing cohorts with matched disease o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gajic, Zoran Z., Deshpande, Aditya, Legut, Mateusz, Imieliński, Marcin, Sanjana, Neville E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270330/
https://www.ncbi.nlm.nih.gov/pubmed/35803911
http://dx.doi.org/10.1038/s41467-022-31055-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270330/
https://www.ncbi.nlm.nih.gov/pubmed/35803911
http://dx.doi.org/10.1038/s41467-022-31055-3

Ejemplares similares